Wells Fargo & Company Downgrades Blueprint Medicines (NASDAQ:BPMC) to Hold
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $129.00 target price on the biotechnology company’s stock, down from their prior target price of $143.00. Wells […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $129.00 target price on the biotechnology company’s stock, down from their prior target price of $143.00. Wells […]
